Objectives: Our aim was to conduct a multicentre study involving laboratories participating in the European TB Reference Laboratory Network aiming to develop a pilot external quality assessment (EQA) scheme for drug susceptibility testing (DST) of non-tuberculous mycobacteria (NTM).
Introduction
The term non-tuberculous mycobacteria (NTM) is commonly used for a large group of mycobacterial species other than Mycobacterium tuberculosis complex (MTBC) and Mycobacterium leprae comprising at present .150 species. 1 NTM are opportunistic bacterial pathogens widely present in environmental reservoirs, predominantly water, from where humans may acquire infection. While recommendations outlining key principles of diagnosis and treatment of NTM disease have been published by the American Thoracic Society (ATS) and IDSA in 2007, data on prevalence of NTM disease and associated species are scarce. 2 This is in part because NTM disease, unlike TB, is not commonly notifiable. [1] [2] [3] [4] [5] [6] However, the incidence of NTM-associated pulmonary disease has been increasing steadily in Canada, the USA, the UK and other countries, which is not exclusively attributable to improvements in laboratory diagnosis. [3] [4] [5] NTM disease is often associated with poor treatment success rates 3, 7 that may be explained by limited availability and poor tolerability of active drugs as well as high prevalence of comorbidities in affected patients. Notably, few studies systematically investigating treatment outcomes of defined therapeutic regimens are available. 2, 4, 8, 9 In addition, the role and clinical relevance of drug susceptibility testing (DST) remains controversial for many species-drug combinations due to a lack of data on the correlation between in vitro test results and clinical response. 10, 11 Phenotypic DST (pDST) for NTM is technically challenging due to difficulties in inoculum calibration, drug instability and trailing growth, as well as a lack of standardized interpretive criteria. [11] [12] [13] Broth microdilution (BMD) is considered the reference pDST method for most NTM. 8, 11, 14 Good analytical performance of commercially available microdilution assays has recently been reported. 13, 15, 16 Other methods, including disc diffusion, gradient diffusion and agar-based assays, are still in use in some laboratories despite the lack of reproducibility and absence of established breakpoints. 11, 17 These issues cannot be resolved without development and implementation of a rigorous quality assurance system based on widely agreed principles. Existing external quality assessment (EQA) schemes for MTBC diagnostic laboratories include those provided by the National External Quality Assessment Service (NEQAS), the College of American Pathologists (CAP), the WHO, the European TB Reference Laboratory Network (ERLTB-Net) and Instand, but none of these covers DST for NTM. 18 Recognizing an urgent need for harmonizing methodologies employed for NTM identification and DST, we conducted a multicentre study involving national reference laboratories (NRLs) participating in ERLTB-Net. The study aimed to investigate methodologies employed for NTM identification and DST, and to develop a pilot EQA scheme in order to improve quality and clinical relevance of these services.
Materials and methods
The study comprised two phases: (i) a survey determining laboratory services offered and methods used for identification and DST of NTM; and (ii) a multicentre EQA DST study using a panel of 10 clinical NTM isolates.
For the survey, a structured questionnaire was developed and sent to all ERLTB-Net member laboratories (n " 32) in 28 EU member states to collect information methods used for NTM identification and DST. Results of the survey were analysed and utilized as the basis for the second part of the study (pilot EQA scheme).
Within the pilot EQA scheme, identical panels comprising five slowly (Mycobacterium avium; MAV) and five rapidly (Mycobacterium abscessus; MAB) growing bacterial isolates were sent to 22 ERLTB-Net laboratories performing NTM DST routinely and expressing an interest in participating in this part of the study. Isolate panels were prepared by the NRL at Research Centre Borstel, Germany. For MAV, identification was performed by GT CM assay (HAIN Lifescience, Nehren, Germany). For MAB, subspecies identification was performed using the NTM-DR line-probe assay (HAIN Lifescience) and Sanger sequencing (strains MAB6, MAB8 and MAB10, M. abscessus subsp. abscessus; strain MAB7, M. abscessus subsp. massiliense; and strain MAB9, M. abscessus subsp. bolletii). All isolates were subjected to pDST (RAPMYCOI and SLOMYCOI broth microdilution assays, TREK Diagnostics/ Thermo Fisher, Bremen, Germany) and genotypic DST (gDST; NTM-DR assay) twice before sending the isolates to participating laboratories (MIC readings were within +1 log 2 for all isolates and tested drugs). All DST assays were set up, read and interpreted in strict accordance with the manufacturers' and CLSI recommendations.
14 erm(41) and rrl genotypes for MAB isolates were C28/WT (MAB8 and MAB10, macrolide susceptibility), T28/WT (MAB6 and MAB9, inducible macrolide resistance) and C28/A2058C (MAB7, constitutional high-level resistance).
The investigated compounds were chosen based on the availability of tentative interpretive criteria as stated in CLSI document M24-A2. 14 . Carbapenems were not included in this pilot study because of known testing difficulties due to drug instability. 19 MIC values and interpretations (resistant/susceptible/intermediate/unable to interpret) were recorded using the reporting forms provided and were returned to the study coordinators (National Reference Centre for Mycobacteria, Borstel, Germany and PHE, London, UK) within 2 months of the date of distribution.
Consensus modal MIC values were determined based on the reports received from participating laboratories. MIC values within +1 log 2 step of the consensus MIC were considered to be in EA. For categorical agreement (CA), numbers of very major errors (vMEs; resistant isolate reported as susceptible), major errors (MEs; susceptible isolate reported as resistant) and minor errors (mEs; susceptible versus indeterminate and/or resistant versus indeterminate) were calculated. 15 
Results

Phase 1: survey
Information on laboratories participating in both phases of the study are summarized in Figure S1 (available as Supplementary data at JAC Online). The majority of the laboratories (22/30; 73.3%) utilized Hain GT CM and Hain GT AS line-probe assays (Hain Lifescience) as the primary and secondary means of NTM speciation, respectively. Three laboratories and one laboratory used targeted Sanger sequencing and MALDI-TOF MS, respectively, for initial species identification. Twelve NRLs (40%) employed targeted sequencing as additional means for further speciation of NTM not identifiable using line-probe assays (Table S1 ). In 12 laboratories (40.0%), the Hain NTM-DR assay was in use for identification of Mycobacterium chimaera.
Most laboratories (17/24; 70.8%) used a commercial BMD assay (all RAPMYCOI and SLOMYCOI plates) for NTM DST. Other methodologies included a gradient diffusion method, proportion methods on solid and liquid (MGIT 960) media and the agar dilution method on 7H10 medium (two laboratories, three laboratories, four laboratories and one laboratory, respectively). Fifteen laboratories (62.5%) employed gDST assays for detection of mutations in genes associated with resistance to macrolides and aminoglycosides (all Hain GT NTM-DR). The majority of participating laboratories (n " 23; 95.8%) performed DST on clinicians' request only.
Phase 2: pilot EQA
Twenty-two laboratories expressed their interest in participating in phase 2 and were sent isolate panels. Completed forms reporting MICs and interpretations (where possible) for slowly and rapidly growing NTM were received from 14/22 (63.6%) and 16/22 (72.7%) laboratories, respectively, all of whom performed pDST by the BMD method. One of the five included MAV isolates was found to be contaminated and was excluded from further analyses. The summary MIC distributions for the five MAB and four MAV isolates, the MIC values determined by NRL Borstel and the corresponding EA rates are depicted in Figures 1 and 2 and in Tables 1 and 2. MIC distributions were mostly unimodal, with occasional truncation at the upper end of the tested concentration range, e.g. with MAV and amikacin. MIC values of clarithromycin varied within + 2 log 2 steps in MAV (overall MIC range " 0.5-8 mg/L, EA " 92.3%) while wider variation (0.06-16 mg/L, EA " 76.1%) was seen in MAB isolates. In particular, five and four laboratories reported too low MIC values, resulting in false susceptibility for strains MAB6 and MAB9, respectively, both of which showed an inducible macrolide resistance phenotype (Figure 2 ). Reported MICs of amikacin varied from 2 to 64 mg/L and from 0.5 to 64 mg/L for MAV and MAB, respectively, resulting in EA rates of 78.8% and 76.0%. Somewhat narrower ranges (+2 log 2 ) were observed for moxifloxacin for both MAV and MAB (MIC " 0.5-8 mg/L and EA " 90.0%, and MIC " 0. Nikolayevskyy et al. Tables 3 and 4 . For clarithromycin, CA was 100% for MAV and 82.4% for MAB (vMEs, n " 9; MEs, n " 2; mEs, n " 1). For amikacin and MAV, no CA could be determined due to missing breakpoints. For MAB, CA was 90.0% (vMEs, n " 3; MEs, n " 1; mEs, n " 3). CA for moxifloxacin was 56.8% in MAV (vMEs, n " 2; mEs, n " 16) and 84.4% in MAB (vMEs, n " 1; mEs, n " 9). For linezolid, CA was 81.8% in MAV (vMEs, n " 3; mEs, n " 9) and 53.6% in MAB (vMEs, n " 4; MEs, n " 18; mEs, n " 20). CA for doxycycline was 100% in MAB. For MAV and doxycycline, no CA could be determined due to missing breakpoints.
Discussion
This pilot multicentre study reports the first EQA data focused on NTM DST. Its results demonstrate significant heterogeneity regarding both absolute MIC values and categorical results reported by participating laboratories for the most common pathogenic rapidly growing mycobacteria (RGM) and slowly growing mycobacteria (SGM) species, i.e. MAB and MAV. This heterogeneity cannot be explained by different DST techniques, as all laboratories participating in phase 2 were using the BMD method. Reasons for the heterogeneity of reported results across different laboratories thus are likely to include variations in inoculum preparation, incubation times and interpretation of what the reader considered bacterial growth.
Bacterial inoculum density, age of the culture from which the inoculum is prepared and incubation time are well-known factors influencing MIC determination by the BMD method. 8, 14 According to CLSI recommendations also reflected in the manufacturer's instructions for the BMD plates, reading of MIC plates should be performed between days 3 and 5 for RGM and between days 7 and 14 for SGM. [14] [15] [16] For MAB, an important exception is clarithromycin as plates need to be read again for up to 14 days to control for inducible resistance mediated by the ribosomal methyltransferase Erm(41). 20, 21 Remarkably, a substantial number of participating laboratories did not detect resistance in the two MAB isolates that harboured an inducible erm(41) gene. Lastly, reading of NTM MIC plates is often difficult, e.g. due to inhomogeneous growth, skipped wells or trailing endpoints.
14 However, as detailed information on local procedures regarding inoculum preparation, incubation times and criteria for bacterial growth was not obtained in this pilot study, the exact contribution of these factors to the observed variation in test results remains subject to further investigations.
BMD is a widely recognized standardized method for pDST of RGM and SGM. 8, 11, 14 However, NTM DST needs rigorous quality control using reference strains to ensure not only quality testing but also reproducibility of MICs within recommended ranges. The few studies that investigated reproducibly of NTM DST using BMD showed good intralaboratory reproducibility. 15, 16, 22 Thus, rigorous training and standardized reading are essential to obtaining more reproducible results.
In order to develop a future EQA scoring system, we analysed the obtained data by determination of EA and CA across participants. Interestingly, high EA did not necessarily imply high CA, e.g. with moxifloxacin and MAV (EA " 90.0% and CA " 56.8%), and with linezolid and MAB (EA " 79.7% and CA " 53.6%). This observation cannot be explained by insufficient interlaboratory reproducibility, as in that case both EA and CA would have been low. For moxifloxacin, all MAV isolates belonged to the WT population with modal MICs of 2-4 mg/L. 23 Using the current CLSI clinical breakpoint (CBP) indicating 'resistance' (4 mg/L) and assuming a technical imprecision of the BMD method of at least +1 log 2 step, miscategorization in this case is not due to interlaboratory inconsistencies but to the CBP splitting the WT population. The same is true for MAB and linezolid. With modal MICs of 4 and 16 mg/L, all isolates belonged to the WT population. Here, the breakpoint indicating 'susceptibility' (8 mg/L) splits the WT population, leading to similar inconsistencies. Of note, the issue of MEs and vMEs due to CBPs splitting bacterial WT populations has previously been reported for other bacterial pathogens. 24 For a future NTM EQA scheme, we propose to deduct one scoring point for every incorrect MIC (outside +1 log 2 ) and one point for incorrect interpretation. With 10 isolates and 5 drugs being scored per isolate, 40 points and more (i.e. 80% correct results) would result in a laboratory's performance considered satisfactory and an EQA certificate being issued. In the current pilot study, 9 out of 16 laboratories taking part in the EQA scheme demonstrated performance of .80% ( Figure S2) .
In order to reflect the technical issues related to some of the current CBPs, we also suggest excluding species-drug combinations from assessment of CA in cases where the reference MIC is +1 log 2 step from a CBP. In this pilot study, however, removal of species-drug combinations with reference MICs +1 log 2 step from a CBP would have resulted in removal of 12 strain-drug combinations, pointing to the need for careful strain selection in future EQA schemes. Nikolayevskyy et al.
This study has several limitations. Firstly, for logistical reasons, we only included 10 isolates and focused on MAV and MAB. As a result, we could not perform an in-depth statistical analysis. Secondly, we have not specifically requested and collected information on local procedures for performing DST for NTM including inoculum preparation, incubation times and criteria for bacterial growth. Not all laboratories performing NTM DST participated in the EQA scheme due to financial and logistical reasons. Also, other DST methods such as line-probe assays or other phenotypic tests were not further evaluated in this pilot study.
In summary, broad application of a quality-controlled and standardized consensus technique is the first step towards more reliable and reproducible NTM DST. Our results show that interlaboratory reproducibility for NTM DST is insufficient, highlighting the need for expanding EQA schemes to clinically relevant NTM. In addition, the data generated from this study indicate the need for re-evaluation of NTM epidemiological cut-off values (ECOFFs) and CBPs with respect to technical impediments, e.g. in the context of a future EUCAST recommendation. As EQAs have led to more reliable and reproducible pDST for MTBC, we propose to follow a similar approach for clinically relevant NTM. EQA scheme for NTM drug susceptibility testing JAC
